Skip to main content
Pancreatic Cancer Treatment Targeting the Piezo1/TRPV4 Axis

Pancreatic Cancer Treatment Targeting the Piezo1/TRPV4 Axis

Unmet Need Pancreatic cancer remains one of the most lethal cancers, with a 5-year survival rate of only 5–10%. In the U.S. alone, an estimated 64,000 people will be diagnosed each year, with over 55,000…

Read More

A novel T-cell-based immunotherapy for brain cancer

A novel T-cell-based immunotherapy for brain cancer

Unmet Need Cancer immunotherapy represents a new paradigm in cancer treatment with the goal of harnessing the immune system to selectively attack a patient’s tumor. T-cell-based immunotherapies encompass chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes,…

Read More

PD-L1-Based Therapy for Non-Opioid Treatment of Chronic Pain

PD-L1-Based Therapy for Non-Opioid Treatment of Chronic Pain

Unmet Need Chronic pain, including inflammatory, neuropathic, and cancer-related pain, remains difficult to manage without opioids, which pose risks of addiction and adverse side effects. Existing non-opioid treatments often fail to provide sufficient relief or…

Read More

Acoustofluidic technologies for precision control in microfluidic systems

Acoustofluidic technologies for precision control in microfluidic systems

Unmet Need Achieving precise manipulation of particles, cells, and droplets in microscale liquid systems is a major challenge in life sciences, material sciences, and chemistry. Traditional microfluidic systems, which use hydrophobic channels and pressure differentials…

Read More

Novel RNA-based anti-cancer therapeutic for sustained immunotherapy by combined pattern recognition receptor (PRR) activation and anti-microRNA therapy (AMT)

Novel RNA-based anti-cancer therapeutic for sustained immunotherapy by combined pattern recognition receptor (PRR) activation and anti-microRNA therapy (AMT)

Unmet Need Cancer is incredibly prevalent and current therapies are insufficient. Globally, lifetime prevalence is 1 in 5, and mortality is 1 in 9 in men and 1 in 12 in women. Solid tumors account…

Read More

Method for the in vitro differentiation of human dendritic cells from hematopoietic stem cells for research and immunotherapy development

Method for the in vitro differentiation of human dendritic cells from hematopoietic stem cells for research and immunotherapy development

Unmet Need Dendritic cells (DCs) play a critical role in the adaptive immune response by capturing and presenting antigens to activate cytotoxic T-cells. As such, naturally occurring DCs are thought to have crucial antitumor activity…

Read More

Method to overcome treatment resistant cancer by rescuing STING signaling

Method to overcome treatment resistant cancer by rescuing STING signaling

Unmet Need Among types of brain cancer, glioblastoma (GBM) is the most common and the most devastating. Over 8000 patients are diagnosed annually in the United States, accounting for half of all primary malignant brain…

Read More

Rapid non-invasive optical assay system for intraoperative breast tumor margin assessment

Rapid non-invasive optical assay system for intraoperative breast tumor margin assessment

Unmet Need Breast cancer is the most common non-skin cancer in women in the United States, accounting for 1 in 3 of all new female cancers each year. Breast conserving surgery is a common treatment…

Read More

A novel non-addictive method for treating neuropathic pain associated with cancer

A novel non-addictive method for treating neuropathic pain associated with cancer

Unmet Need In the US alone, close to 1.9 million new cases of cancer are diagnosed each year and 44.5% of these patients will experience chronic pain. This type of chronic pain, called neuropathic pain,…

Read More

New small molecules targeting castration-resistant prostate cancer

New small molecules targeting castration-resistant prostate cancer

Unmet Need Prostate cancer (PC) is the second most common male cancer globally and represents 15% of all cancers diagnosed in males. An estimated 34,700 deaths were predicted to occur from PC in the U.S.…

Read More

Revolutionary inhibitor target for enhanced immune response against breast cancer relapse

Revolutionary inhibitor target for enhanced immune response against breast cancer relapse

Unmet Need In the US, it is estimated that 1 in 8 women will develop breast cancer, of which 78% are estrogen receptor-positive (ER+) cases. These ER+ breast cancers are known for their risk of…

Read More

Therapy for neurotensin positive cancers

Therapy for neurotensin positive cancers

Unmet Need Under normal conditions, neurotensin signaling is largely constrained to the nervous system. However, abnormal expression is seen in cancers that are aggressive or have a poor prognosis such as pancreatic, which has a12.5%…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us